Abstract: The invention relates to a method of inhibiting the cytotoxic activity of extracellular histones in a subject, comprising administering an effective amount of a polyanion to the subject. In particular the invention relates to a method for the treatment of patients who are suffering from sepsis and employs polyanions to rapidly form complexes with and thus neutralize or inhibit the cytotoxic activity of extracellular histone proteins, for example, those found in the blood circulation of sepsis patients.
Type:
Grant
Filed:
November 29, 2011
Date of Patent:
January 5, 2016
Assignee:
THE AUSTRALIAN NATIONAL UNIVERSITY
Inventors:
Ross Wentworth Stephens, Christopher Richard Parish, Craig Geoffrey Freeman, Timothy John Senden
Abstract: This invention relates to synthetic oligo- or multivalent beta-1-2-linked mannooligosaccharide compounds and to their use for modulating T helper (Th) and T regulatory (Treg) cell-mediated immune responses.
Type:
Grant
Filed:
June 21, 2012
Date of Patent:
December 29, 2015
Assignees:
ABO AKADEMI UNIVERSITY, TURUN YLIOPISTO
Inventors:
Johannes Savolainen, Kaarina Mäkinen, Reko Leino, Chinmoy Mukherjee
Abstract: The present invention aims to provide a hydrophilic modified polyrotaxane composition having excellent storage stability. The present invention relates to a hydrophilic modified polyrotaxane composition comprising: a hydrophilic modified polyrotaxane produced by modifying, with hydrophilic modifying groups, all or part of hydroxy groups on a cyclodextrin of a polyrotaxane containing the cyclodextrin, a polyethylene glycol which is included in the cavities of the cyclodextrin molecules in a skewered manner, and a capping group that is placed at each end of the polyethylene glycol and prevents dissociation of the cyclodextrin molecules from the polyethylene glycol; and a polyphenol antioxidant.
Type:
Grant
Filed:
December 5, 2011
Date of Patent:
December 8, 2015
Assignees:
SUMITOMO SEIKA CHEMICALS CO., LTD., ADVANCED SOFTMATERIALS INC.
Abstract: The present invention is directed to the use of chitosan, a chitosan derivative or a physiologically acceptable salt thereof, to increase nail growth rate. The invention is further directed to the use of chitosans to accelerate nail growth rate during treatment of nail illnesses, nail dystrophy or other nail conditions, in order to shorten considerably the specific treatments of said nail illnesses, nail dystrophy or other nail conditions.
Abstract: Poly alpha-1,3-glucan ether compounds are disclosed herein with a degree of substitution of about 0.05 to about 3.0. Also disclosed are methods of producing poly alpha-1,3-glucan ether compounds.
Type:
Grant
Filed:
December 16, 2013
Date of Patent:
September 22, 2015
Assignee:
E I DU PONT DE NEMOURS AND COMPANY
Inventors:
Jayme L Paullin, Andrea M Perticone, Rahul B Kasat, T Joseph Dennes
Abstract: The present invention is directed to methods for treating orthomyxovirus infections comprising administering to a subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
Abstract: The present invention provides methods for treating acute kidney injury through introduction of one or more drag reducing polymers, oligomers, and/or monomers, as well as compositions that include therapeutic amounts of one or more of these drag reducing polymers, oligomers, and/or monomers. These compositions may also include additional components that enhance at least one of the stability, effectiveness, or administerability of the polymers, oligomers, and/or monomers—such as buffers, anti-oxidants, and enzyme inhibitors.
Abstract: This invention relates to compositions for reducing the absorption or bioavailability of lipids in the gastrointestinal tract, and to methods for the preparation and use of these compositions. The compositions comprise a source of dietary fiber together with a cyclodextrin. The compositions of the invention are suitable for use in the prevention and treatment of obesity or hyperlipidaemia.
Type:
Grant
Filed:
May 13, 2011
Date of Patent:
August 18, 2015
Assignee:
INQPHARM GROUP SDN. BHD.
Inventors:
Pee Win Chong, Thomas Hafner, Istvan Puskas
Abstract: Among other things, the present disclosure provides methods for enriching, identifying, and/or quantifying unusually modified glycans (e.g., phosphorylated glycans, sulfated glycans, and/or multi-acetylated glycans). In many embodiments, methods comprise providing a glycan preparation from which sialic acids have been released; subjecting the sialidase-treated glycan preparation to a separation technique that separates glycans based on charge-to-mass ratio; and quantifying the charged products using at least one quantification standard.
Type:
Grant
Filed:
December 18, 2009
Date of Patent:
August 11, 2015
Assignee:
Momenta Pharmaceuticals, Inc.
Inventors:
Carlos J. Bosques, Jennifer Lynn Murphy, Sibel Nur Gunay, Zachary Shriver, Cuihua Liu
Abstract: The invention relates to compositions and methods for treating kidney and muscle dysfunction that involves use of therapeutic amounts of N-acetyl mannosamine.
Type:
Grant
Filed:
March 8, 2013
Date of Patent:
August 4, 2015
Assignee:
The United States of America as represented by the Secretary of the Department of Health and Human Services
Inventors:
Marjan Huizing, William A. Gahl, Irini Manoli, Enriko Klootwijk
Abstract: Chiral salts comprising anionic cyclodextrin derivatives with particular types of non-metal cations are provided. The anionic CD derivative salts can serve as ionic liquids and can possess substantial advantages over currently commercially available ionic liquids particularly for use as chiral phase transfer catalyst, chiral reaction medium, chiral extraction medium, and/or as chiral additive to a chemical process. Methods of preparing the same are provided.
Abstract: The present invention relates to an injectable dermal filler composition that can be injected into the skin of the orbital trough of a patient without aggravating darkness around the eyes of the patient. In fact, this composition can be used to lighten such dark areas which have developed over time. The present invention more specifically discloses an injectable dermal filler composition comprising hyaluronic acid and a white colorant. The present invention further reveals a method for treating wrinkles and firming an area of skin on a human patient comprising injecting an injectable dermal filler composition comprising hyaluronic acid and a white colorant, into the area of skin on the human patient.
Abstract: The invention provides the use of a cyclodextrin compound for the manufacturing of a medicament for the treatment or prevention of bronchial inflammatory diseases, particularly for asthma and chronic obstructive pulmonary disease (COPD).
Abstract: A method of inhibiting inflammation in a subject comprising the administration of milk oligosaccharides or glycoconjugates containing milk oligosaccharides is disclosed.
Type:
Grant
Filed:
July 2, 2010
Date of Patent:
May 19, 2015
Assignees:
Children's Hospital Medical Center, The General Hospital Corporation, Instituto Nacional de Ciencias Medicas Y Nutricion
Inventors:
Ardythe L. Morrow, David S. Newburg, Guillermo M. Ruiz-Palacios
Abstract: The present invention is directed to a novel process for the preparation of compounds having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.
Inventors:
Ahmed F. Abdel-Magid, Maureen Chislom, Steven Mehrman, Lorraine Scott, Kenneth M. Wells, Fan Zhang-Plasket, Sumihiro Nomura, Mitsuya Hongu, Yuichi Koga
Abstract: A method of treating intrauterine inflammation in a subject associated with intrauterine bacterial infection includes administering to the subject a therapeutically effective amount of a toll-like receptor 4 antagonist. The therapeutically effective amount administered to the subject is an amount effective in reducing intrauterine inflammation in the subject.
Abstract: The invention relates to a pharmaceutical formulation that contains a complex of a propofol salt with a cyclodextrin. The invention makes it possible to provide propofol in a formulation that can be stored and that can be administered intravenously without problems.
Abstract: An aripiprazole formulation is provided which includes the antipsychotic agent aripiprazole in the form of an inclusion complex in a ?-cyclodextrin, preferably, sulfobutyl ether ?-cyclodextrin (SBECD), which in the form of an injectable produces reversible generally minimal to mild irritation at the intramuscular injection site. A method for minimizing or reducing irritation caused by aripiprazole at an intramuscular injection site and a method for treating schizophrenia employing the above formulation are also provided.
Abstract: The invention provides a compound that is a CETP activity inhibitor. The compound can increase HDL and at the same time decrease LDL through selective inhibition of CETP activity. the invention also provides for the use of the compound to prevent or treat atherosclerosis or hyperlipidemia.